A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia

Trial Profile

A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Haematopoetic stem cell therapy Nohla Therapeutics (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms LAUNCH
  • Sponsors Nohla Therapeutics
  • Most Recent Events

    • 03 Oct 2017 Status changed from planning to not yet recruiting.
    • 04 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top